E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
Acquired angioedema due to C1-inhibitor deficiency |
Verworven angio-oedeem op basis van een C1-esterase remmer deficiëntie |
|
E.1.1.1 | Medical condition in easily understood language |
Acquired angioedema due to C1-inhibitor deficiency |
Verworven angio-oedeem op basis van een C1-esterase remmer deficiëntie |
|
E.1.1.2 | Therapeutic area | Diseases [C] - Skin and Connective Tissue Diseases [C17] |
MedDRA Classification |
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 21.0 |
E.1.2 | Level | PT |
E.1.2 | Classification code | 10081035 |
E.1.2 | Term | Acquired C1 inhibitor deficiency |
E.1.2 | System Organ Class | 10040785 - Skin and subcutaneous tissue disorders |
|
E.1.3 | Condition being studied is a rare disease | Yes |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
To evaluate the efficacy of long-term prophylactic treatment with deucrictibant (PHA-022121) once daily in preventing angioedema attacks in patients with acquired C1 inhibitor deficiency. |
Het primaire doel is het onderzoeken van de effectiviteit van langdurig gebruik van deucrictibant (PHA-022121) met betrekking tot het voorkomen van angio-oedeem aanvallen bij patiënten met verworven C1-esteraseremmer deficiëntie. |
|
E.2.2 | Secondary objectives of the trial |
To evaluate the safety of long-term prophylactic use of deucrictibant (PHA-022121) and to further explore the clinical efficacy of deucrictibant (PHA-022121) with regard to quality of life, treatment satisfaction and frequency and timing of on demand medication use. |
Het onderzoeken van de veiligheid van langdurig profylactisch gebruik van deucrictibant (PHA-022121) en het verder onderzoeken van de klinische werkzaamheid van deucrictibant (PHA-022121) met betrekking tot kwaliteit van leven, patiëntentevredenheid ten aanzien van de medicatie en frequentie en timing van gebruik van aanvalsbehandeling. |
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
• Provision of signed and dated informed consent form • Male or female, aged > 35 at enrolment • Diagnosis of AAE-C1-INH based upon all of the following: 1. Documented clinical history consistent with AAE-C1-INH (subcutaneous or mucosal, nonpruritic swellings without accompanying urticaria and C1-INH activity < 0.63mE/L) 2. At least one of the following: • Age at reported onset of first angioedema symptoms ≥ 40 years AND family history negative for angioedema • C1q below lower limit of normal (88 kU/L) AND absence of SERPING1 mutation • Serological confirmation of antibodies against C1-INH • Documented history of at least three angioedema attacks in the last four months, or at least two angioedema attacks in the last two months. For patients that previously participated in POP-AID part 2, a historical attack-rate of at least three attacks in four months or two attacks in two months previous to the start of POP-AID part 2 is required • Reliable access to and experience with using icatibant to effectively manage acute angioedema attacks • Female patients of childbearing potential must agree to be abstinent or to use highly effective forms of contraception methods from enrolment through the end of the study. This includes progestin-only oral contraceptive associated with inhibition of ovulation (oral, injectable, or implantable), intrauterine device (IUD, all types) or intrauterine hormone releasing systems (IUS). A female of childbearing potential whose male partner has had a vasectomy must agree to use one additional form of medically acceptable contraception. • Male patients, including males who are surgically sterile (post vasectomy), who have a female partner of childbearing potential must agree to be sexually abstinent or use a medically acceptable form of barrier contraception for two weeks after each administration of study drug. In addition, they must agree to not donate sperm during study participation.
|
- Getekend en gedateerd toestemmingsformulier - >35 jaar oud bij screening - Diagnose verworven C1-esterase deficiëntie gebaseerd op basis van: 1. Gedocumenteerde medische voorgeschidenis passend hierbij (niet-jeukende zwellingen van de huid of slijmvliezen zonder urticaria en een C1-esterase activiteit kleiner dan 0.63mE/L. 2. Tenminste één van de volgende: + Leeftijd bij ontstaan van de eerste angio-oedeem symptomen ≥ 40 jaar én negatieve familiegeschiedenis voor angio-oedeem + C1q onder de laagste normaalwaarde (88 kU/L) én afwezigheid van SERPING1 mutatie + Serologische bevestiging van antilichamen tegen C1-esteraseremmer - Gedocumenteerde voorgeschiedenis van tenminste 3 angio-oedeem aanvallen in de laatste 4 maanden, of tenminste 2 aanvallen in de laatste 2 maanden. Voor POP-AID deelnemers geldt een historische aanvalsfrequentie van ten minste 3 aanvallen in de 4 maanden of 2 aanvallen in de 2 maanden voorafgaande aan de start van POP-AID deel 2. - Toegang tot en ervaring met icatibant om acute aanvallen te behandelen - Indien van toepassing: gebruik van zeer effectieve anticonceptiemethoden |
|
E.4 | Principal exclusion criteria |
• Pregnancy or breast-feeding • Clinically significant abnormal ECG, most notably a QTcF > 470 ms (for females) or > 450 ms (for males) • Any clinically significant history of angina, myocardial infarction, syncope, stroke, left ventricular hypertrophy or cardiomyopathy, or any other cardiovascular abnormality within the previous year • Any other systemic disease (e.g., gastrointestinal, renal, respiratory, neurological) or significant disease or disorder that would interfere with the patient’s safety or ability to participate in the study • Active infection with human immunodeficiency virus (HIV) or hepatitis B virus (HBV) or hepatitis C virus (HCV) • History of abnormal hepatic function (AST > 2×ULN, ALT > 2×ULN, or total bilirubin > 1.5×ULN) • History of abnormal renal function (eGFR CKD-EPI < 60 mL/min/1.73 m2) • History of alcohol or drug abuse within the previous year, or current evidence of substance dependence or abuse (self-reported alcoholic intake > three drinks/day) • History of documented severe hypersensitivity to any medicinal product • Participation in any investigational drug study within five half-lives of study drug at enrolment • Regular use of corticosteroids, antihistamines, narcotics, and other pain relief medications for acute angioedema attack treatment • Use of concomitant medication that are moderate or potent inhibitors/inducers of CYP3A4 or are metabolized by CYP3A4 and have a narrow therapeutic range, such as clarithromycin, erythromycin, diltiazem, itraconazole, ketoconazole, ritonavir, verapamil, goldenseal and grapefruit as well as phenobarbital, phenytoin, rifampicin, St. John's Wort, and glucocorticoids (not for topical use or inhalation)
|
- Zwanger of borstvoeding gevend - Klinisch significant abnormaal ECG, met name QTc verlenging - Klinisch significante voorgeschiedenis van angina pectoris, myocard infarct, syncope, herseninfarct, linkerventrikehypertrofie of cardiomyopathie of een andere cardiovasculaire aandoening in het afgelopen jaar. - Systemische aandoeningen (bijvoorbeeld gastrointestinaal, renaal, pulmonaal, neurologisch) of andere aandoening die interfereert met de veiligheid of mogelijkheid van de patiënt om in de studie te participeren. - Actieve infectie met HIV of hepatitis B/C - Voorgeschiedenis van abnormale leverfunctie (ASAT > 2x ULN, ALAT > 2x ULN of totaal bilirubine > 1.5x ULN) - Voorgeschidenis van abnormale nierfunctie (eGFR CKD-EPI < 60 mL/min/1.73 m2) - Voorgeschiedenis van alcohol of drugsmisbruik in het afgelopen jaar - Voorgeschiedenis van ernstige hypersensitiviteit voor een medicijn - Deelname aan een andere interventiestudie met medicatie binnen 5 maal de half-waarde tijd van de studiemedicatie - Regelmatig gebruik van corticosteroïden, antihistminica of pijnstillers voor acute angio-oedeemaanvallen - Gebruik van medicatie die CYP3A4 remmen/induceren of hierdoor gemetaboliseerd worden |
|
E.5 End points |
E.5.1 | Primary end point(s) |
Normalized number of investigator-confirmed angioedema attacks |
Het aantal angio-edeem aanvallen (bevestigd door de onderzoeker) |
|
E.5.1.1 | Timepoint(s) of evaluation of this end point |
Normalized number of investigator-confirmed angioedema attacks per four weeks of exposure compared to baseline (deucrictibant (PHA-022121) naive participants) or before treatment with deucrictibant (PHA-022121) (previous POP-AID part 2 participants) |
Het aantal angio-edeem aanvallen (bevestigd door de onderzoeker) per 28 dagen behandeling in vergelijking met de historische aanvalsfrequentie. |
|
E.5.2 | Secondary end point(s) |
• Number of investigator-confirmed moderate or severe angioedema attacks during the treatment period • Number of investigator-confirmed angioedema attacks requiring acute treatment during the treatment period • Duration in days of the longest attack free interval • Change from baseline (deucrictibant (PHA-022121) naïve patients) or change from before treatment with deucrictibant (PHA-022121) (previous POP-AID part 2 participants) in the Angioedema Control Test (AECT) • Change from baseline (deucrictibant (PHA-022121) naïve patients) or change from before first prophylactic treatment with deucrictibant (PHA-022121) (previous POP-AID part 2 participants) in the Angioedema Quality of Life (AE-QoL) after completion of the treatment period • AE-QoL-score at 1, 3, 6, 9 and 12 months • Treatment satisfaction questionnaire for Medication (TSQM) at 1, 3, 6, 9 and 12 months • Occurrence of treatment-emergent adverse events (TEAEs), treatment-related adverse events (AEs), and treatment-emergent serious adverse events (TESAEs), including clinically significant changes in clinical laboratory tests, vital signs or ECG reported as AE
|
Effectiviteit: - Het aantal matige of ernstige angio-oedeem aanvallen gedurende de behandelperiode - Het aantal angio-oedeem aanvallen die acute aanvalsmedicatie behoeven - De duur van de langste aanvalsvrije periode - Angioedema Control Test (AECT) score tov vóór behandeling - Angioedema Quality of Life (AE-QoL) score tov voor behandeling - Angioedema Quality of Life (AE-QoL) score na 1, 3, 6, 9 en 12 maanden behandeling - Treatment satisfaction questionnaire for Medication (TSQM) score na 1, 3, 6, 9 en 12 maanden behandeling
Veilighed: - Het optreden van ongewenste voorvallen tijdens de behandeling |
|
E.5.2.1 | Timepoint(s) of evaluation of this end point |
Secondary endpoints are evaluated after 12 months of treatment. |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | Yes |
E.6.3 | Therapy | No |
E.6.4 | Safety | Yes |
E.6.5 | Efficacy | Yes |
E.6.6 | Pharmacokinetic | No |
E.6.7 | Pharmacodynamic | No |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | No |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | Yes |
E.7.3 | Therapeutic confirmatory (Phase III) | No |
E.7.4 | Therapeutic use (Phase IV) | No |
E.8 Design of the trial |
E.8.1 | Controlled | No |
E.8.1.1 | Randomised | No |
E.8.1.2 | Open | Yes |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | No |
E.8.1.5 | Parallel group | No |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | No |
E.8.2.2 | Placebo | No |
E.8.2.3 | Other | No |
E.8.2.4 | Number of treatment arms in the trial | 1 |
E.8.3 |
The trial involves single site in the Member State concerned
| Yes |
E.8.4 | The trial involves multiple sites in the Member State concerned | No |
E.8.5 | The trial involves multiple Member States | No |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | No |
E.8.6.2 | Trial being conducted completely outside of the EEA | No |
E.8.7 | Trial has a data monitoring committee | No |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 1 |
E.8.9.1 | In the Member State concerned months | 8 |
E.8.9.1 | In the Member State concerned days | |